Posted by Michael Wonder on 30 Jul 2019
EMA grants PRIME access to ProQR’s sepofarsen for Leber’s congenital amaurosis 10
29 July 2019 - Access based on positive interim analysis of clinical data as well as preclinical data to date.
ProQR Therapeutics announced today that its sepofarsen (QR-110) drug candidate, which is being developed for targeting the p.Cys998X mutation in the CEP290 gene for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the PRIority MEdicines (PRIME) program by the EMA.
As of June 2019, less than 30% (54 out of 181) of applications to the PRIME program have been granted access, and only 20% (one out of five) of ophthalmology applications have been granted access.
